MOLBREEVI

LANGHORNE, Pa., July 30, 2026 Savara Inc. announced that the European Patent Office (EPO) and the Australian Patent Office...

Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...

LANGHORNE, Pa., March 30, 2026 Savara Inc. has achieved a major regulatory milestone as the European Medicines Agency (EMA)...

LANGHORNE, Pa., November 2, 2025 — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases,...